Dr. Sui Ziye is our executive Director and the chief executive officer of our Company, a director of Miracogen Shanghai, a director of Taizhou Aoke, an executive director of CtM Bio, and the general manager of Lepu Beijing. In addition, Dr. Sui also serves as a director of Hangzhou HealSun, a company owned by us as to 23.2% and a non-executive director of Star Combo Pharma Limited, a company listed on the Australian Stock Exchange (stock code: S66). Dr. Sui has nearly ten years of managerial experience in the pharmaceutical sector.

Prior to joining our Group, Dr. Sui held several positions at Lepu Medical and its subsidiaries, including an international sales & marketing manager and a vice president of Lepu Medical, a CEO of Comed BV, a CEO of Beijing Lepu Hushengtang Technology Co., Ltd. (北京樂普護生堂網絡科技有限公司), an executive director of Beijing Star GK Medical Device Co., Ltd. (北京思達醫用裝置有限公司), the chairman of the board of Zhongcheng Healthcare Industrial (Hainan) Co., Ltd. (中鋮健康產業(海南)股份有限公司), previously known as Hainan Mingshengda Pharmaceutical Co., Ltd. (海南明盛達藥業有限公司), and a director of Beijing Quinovare Medical Technology Co., Ltd. (北京快舒爾醫療技術有限公司).

Dr. Sui obtained a bachelor’s degree in medical science from Peking University (北京大學) in the PRC in 2001 and a doctoral degree from University of Rochester in the U.S. in 2007.

Dr. Hu Chaohong is our executive Director and co-chief executive officer of our Company, chairman of the board and general manager of Miracogen Shanghai, a company founded by Dr. Hu in 2014, and director of Innocube Limited. Dr. Hu has over twenty years of industry experience in development of therapeutic antibodies, antibody drug conjugates and vaccines.

Prior to founding Miracogen Shanghai, Dr. Hu served as Director of Bioassay Development and Process Analytics department at Seagen Inc. (previously known as Seattle Genetics Inc.), a company listed on the Nasdaq Stock Exchange (stock code: SGEN), from June 2007 to October 2013, the head of Molecular Biology and Clinical Immunology department at GlaxoSmithKline plc, a company listed on the New York Stock Exchange (stock code: GSK), research scientist and then Director of Molecular Biology and Clinical Immunology department at ID Biomedical Corporation, , previously known as ID Vaccine Corporation, a company listed on the Nasdaq Stock Exchange (stock code: IDBE) and delisted in 2005, a postdoctoral fellow at the University of Washington.

Dr. Hu obtained a bachelor of science degree in biochemistry from Wuhan University (武漢大學) in the PRC in 1986 and a Ph.D degree in science from Institute of Biophysics, Chinese Academy of Sciences (中國科學院生物物理研究所) in 1991. Dr. Hu was awarded the second prize of National Natural Science Award (國家自然科學二等獎) by the State Council of the PRC (國務院) in 1995.

Dr. Frederick Herman Hausheer is the Global Chief Medical Officer of our Company. Dr. Hausheer has nearly thirty years of international experience in oncology translational medicine and global Phase I-III commercial oncology drug development. Dr. Hausheer is board certified in internal medicine by the American Board of Internal Medicine. Dr. Hausheer has internationally recognized commercial development and scientific expertise in internal medicine, medical oncology, clinical pharmacology, drug safety, and ICH good clinical practices and pre-clinical research and development of novel therapeutic agents for cancer treatment. He has co-authored over 200 scientific publications and is an inventor/co-inventor on over 400 issued international pharmaceutical patents.

Prior to joining us, Dr. Hausheer served as a senior executive and commercial oncology development advisors of many private and public multi-national oncology biotechnology companies and CROs, including a Global Chief Medical Officer and Senior Vice President of WuXi AppTec, Inc., a company listed on the Stock Exchange (stock code: 2359) and Shanghai Stock Exchange (stock code: 603259), and the founder, Chairman and Chief Executive Officer of BioNumerik Pharmaceuticals for 23 years.

Dr. Hausheer received a bachelor of science degree from Graceland University in the U.S. in 1977, a master of science degree from University of Illinois at Urbana-Champaign in the U.S. in 1979, and his doctoral of medicine degree from University of Missouri-Columbia in the U.S. in 1982. Dr. Hausheer completed his internship and residency training in Internal Medicine at the University of Missouri Columbia in 1985, and completed his post-doctoral fellowship in Medical Oncology at the Johns Hopkins Oncology Center in 1987.

Dr. Hausheer has received a number of prestigious awards and recognitions. Dr. Hausheer is also the recipient of Computerworld Smithsonian Leadership Award for Breakthrough Science at the Smithsonian Institution in 1997.